Document is current

Any future updates will be listed below

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

Crossref DOI link: https://doi.org/10.1186/s13075-015-0516-6

Published Online: 2015-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark